Benefits and risks preferences for new medicines in rare diseases
Orphanet Journal of Rare Diseases has recently published an article quantifying the benefit-risk preferences for new medicines in rare disease patients and… Read more »
Segolene Ayme
Ségolène is Editor-in-chief of Orphanet Journal of Rare Diseases.
Latest posts by Segolene Ayme (see all)
- Benefits and risks preferences for new medicines in rare diseases - 27th May 2016
- If rare diseases are so rare, why do they matter? - 29th February 2016
If rare diseases are so rare, why do they matter?
Dr. Ségolène Aymé is the Editor-in-Chief for Orphanet Journal of Rare Diseases. She is the founder of Orphanet, and chair of the Topic Advisory Group on rare… Read more »